Numelvi 4.8mg Tablet for Dogs

Effective Relief for Canine Allergic Skin Conditions

When your dog experiences persistent itching due to allergic dermatitis or atopic dermatitis, it can significantly impact their quality of life. Numelvi 4.8mg Tablet for Dogs, containing Atinvicitinib 4.8mg w/w, works to target the underlying causes of this itching, helping to restore comfort and reduce scratching.

As a selective Janus kinase (JAK) inhibitor, Atinvicitinib specifically targets the JAK1 enzyme, which plays a crucial role in the inflammation and pruritus pathways. By inhibiting JAK1, Atinvicitinib helps to reduce the inflammatory response and the sensation of itching, allowing your dog to recover and enjoy their daily activities without constant discomfort.

Why Choose Weldricks for Your Dog's Prescription?

At Weldricks Pharmacy, we understand the importance of reliable and accessible veterinary care. Our online pet pharmacy makes it convenient to obtain your dog's prescription medications, delivered directly to your door in discreet packaging. We are a trusted UK-regulated pharmacy, family-run for nearly 100 years, committed to providing professional healthcare solutions for your beloved pets. Our 4.9/5 rating reflects our dedication to excellent service, ensuring you can confidently manage your dog's health needs with us.

Contraindications

• Do not use in cases of hypersensitivity to the active substance (Atinvicitinib) or any of the excipients.

Special Precautions for Use in Target Species

• Safety has not been investigated in dogs younger than 6 months of age or weighing less than 3 kg. Use in such animals should be based on a thorough benefit-risk assessment by a responsible veterinarian.
• Complicating factors, such as bacterial, fungal, or parasitic infections (e.g., fleas, Demodex mites), as well as any underlying causes of allergic and atopic dermatitis (e.g., flea allergy, contact allergy, food allergy), should be investigated and treated concurrently.
• The use of Numelvi 4.8mg Tablet for Dogs has not been evaluated in combination with systemic immunosuppressive agents like glucocorticoids or cyclosporine.
• Safety has not been investigated in dogs with evidence of immunosuppression (e.g., uncontrolled primary hypothyroidism, rickettsial disease) or dogs with evidence of progressive malignant neoplasia. Use in these cases should be based on a benefit-risk assessment by a responsible veterinarian.

Use During Pregnancy, Lactation or in Breeding Animals

• The safety of this veterinary medicinal product has not been established during pregnancy and lactation or in breeding dogs.
• The use of Numelvi 4.8mg Tablet for Dogs is not recommended during pregnancy and lactation.
• Laboratory studies in rats and rabbits have shown effects on prenatal development related to the class of JAK inhibitors.
• The use of this product is not recommended in breeding animals, as laboratory studies in male rats showed an effect on sperm counts and motility.

Adverse Events (Side Effects)

Common adverse events (observed in 1 to 10 animals out of 100 treated) in dogs include:

• Emesis (vomiting)
• Diarrhoea
• Lethargy
• Anorexia (loss of appetite)

It is important to report any adverse events to your veterinarian or the national competent authority to ensure ongoing safety monitoring of veterinary medicinal products.

Overdose Symptoms

While Atinvicitinib has shown high selectivity for JAK1, reducing the potential for adverse effects, significant overdoses may lead to a higher susceptibility to infection, such as bacterial, fungal, and/or parasitic skin disease. In the event of adverse clinical effects following an overdose, the dog should be treated symptomatically.

Special Precautions for the Person Administering the Product

• Wash hands thoroughly with soap and water immediately after administering the veterinary medicinal product.

Disposal of Unused Veterinary Medicinal Products or Waste Materials

• Medicines should not be disposed of via wastewater.
• Utilise take-back schemes for the disposal of any unused veterinary medicinal product or waste materials in accordance with local requirements and national collection systems.

Active Substance

• Atinvicitinib 4.8 mg w/w

Excipients

• Cellulose, microcrystalline
• Lactose monohydrate
• Sodium starch glycolate (type A)
• Tocofersolan
• Hydroxypropylcellulose
• Silica, colloidal anhydrous
• Magnesium stearate

It is crucial to administer Numelvi 4.8mg Tablet for Dogs exactly as prescribed by your veterinary surgeon. They will provide specific dosage instructions based on your dog's weight and condition. Always ensure you follow your vet's advice carefully.

For general guidance, the veterinary medicinal product should be administered once daily at the recommended dose of 0.8 to 1.2 mg atinvicitinib/kg bodyweight at or around the time of feeding. The tablets are breakable along the score line, allowing for precise dosing.

The duration of treatment should be based on an individual benefit-risk assessment by your veterinarian.